Dr. Reid reported that ASCO trials are refining endocrine‑targeted therapy in HR‑positive/HER2‑negative MBC: Inavo 120 extended PFS and added 7 months OS with inavolisib + CDK4/6 inhibitor + fulvestrant in PIK3CA‑mutant disease; SERENA‑6 gave a 9.2‑month PFS edge when switching to camizestrant + CDK4/6 inhibition; VERITECH‑2 added 5 months PFS for ESR1‑mutant tumors on vepdegastrant; and FINER signaled PFS gains from patassertib + fulvestrant in patients with PIK3CA‑pathway alterations.